Company Filing History:
Years Active: 2018
Title: Alan R Eastman: Innovator in Chronic Lymphocytic Leukemia Treatment
Introduction
Alan R Eastman is a notable inventor based in Lebanon, NH (US). He has made significant contributions to the field of medicine, particularly in the treatment of chronic lymphocytic leukemia (CLL). With a total of 2 patents, Eastman has developed innovative methods that aim to improve patient outcomes.
Latest Patents
Eastman's latest patents include a combination treatment protocol and a method for treating chronic lymphocytic leukemia. The combination treatment protocol provides a method for treating CLL using specific medicaments. These medicaments can be pharmaceutical compositions or kits that comprise compounds of formula (I) or a salt, solvate, or prodrug thereof. Notable compounds from his inventions include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran, known as BNC105, and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate, referred to as BNC 105P.
Career Highlights
Eastman is associated with Bionomics Inc., where he continues to work on groundbreaking research and development in the field of oncology. His dedication to advancing treatment options for CLL has positioned him as a key figure in medical innovation.
Collaborations
Throughout his career, Eastman has collaborated with talented individuals such as Darcy Bates and Gabriel Kremmidiotis. These partnerships have contributed to the success of his research and the development of effective treatment protocols.
Conclusion
Alan R Eastman is a distinguished inventor whose work in chronic lymphocytic leukemia treatment has the potential to make a significant impact on patient care. His innovative patents and collaborations reflect his commitment to advancing medical science.